The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters

Trends in Pharmacological Sciences

Volumn 31, Issue 1, 2010, Pages 22-35

  Kis, Olena ^a   Robillard, Kevin ^a   Chan, Gary N Y ^a   Bendayan, Reina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABC TRANSPORTER; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CARRIER PROTEIN; DARUNAVIR; DELAVIRDINE; DIDANOSINE; DIGOXIN; EFAVIRENZ; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPERAMIDE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; SOLUTE CARRIER TRANSPORTER; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE; ZOSUQUIDAR;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TRANSPORT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; MEMBRANE TRANSPORT PROTEINS;

EID: 72749106653     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.10.001     Document Type: Review

References (114)

1. Warnke D., et al. Antiretroviral drugs. J. Clin. Pharmacol. 47 (2007) 1570-1579
2. Piacenti F.J. An update and review of antiretroviral therapy. Pharmacotherapy 26 (2006) 1111-1133
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2008) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services, DHHS, DOI: 1-139. (http://AIDSinfo.nih.gov)
4. Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert. Opin. Drug Metab. Toxicol. 3 (2007) 583-598
5. Kim R.B. Drug transporters in HIV Therapy. Top. HIV. Med. 11 (2003) 136-139
6. Brown K.C., et al. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 48 (2009) 211-241
7. Dickinson, L. et al. (2010) Pharmacokinetics and drug-drug interactions of antiretrovirals: An update. Antiviral Res. 85
8. Ho R.H., and Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78 (2005) 260-277
9. Lee C.G., et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37 (1998) 3594-3601
10. Kim R.B., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101 (1998) 289-294
11. Ronaldson P.T., et al. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm. Res. 21 (2004) 811-818
12. Jones K., et al. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 15 (2001) 675-681
13. Zastre J.A., et al. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J. Neurosci. Res. 87 (2009) 1023-1036
14. Fujimoto H., et al. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol. Pharm. Bull. 32 (2009) 1588-1593
15. Kaddoumi A., et al. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab. Dispos. 35 (2007) 1459-1462
16. van Gelder J., et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab. Dispos. 30 (2002) 924-930
17. Shaik N., et al. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab. Dispos. 35 (2007) 2076-2085
18. Walker D.K., et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. 33 (2005) 587-595
19. Kassahun K., et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35 (2007) 1657-1663
20. Fellay J., et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359 (2002) 30-36
21. Rodriguez-Novoa S., et al. Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics. J. 6 (2006) 234-245
22. Perloff E.S., et al. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33 (2005) 764-770
23. Seminari E., et al. Etravirine for the treatment of HIV infection. Expert Rev. Anti. Infect. Ther. 6 (2008) 427-433
24. Weiss J., et al. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur. J. Pharmacol. 579 (2008) 104-109
25. Perloff M.D., et al. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J. Clin. Pharmacol. 42 (2002) 1269-1274
26. Storch C.H., et al. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 73 (2007) 1573-1581
27. Vishnuvardhan D., et al. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS 17 (2003) 1092-1094
28. Dussault I., et al. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 276 (2001) 33309-33312
29. Dixit V., et al. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab. Dispos. 35 (2007) 1853-1859
30. Perloff M.D., et al. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 14 (2000) 1287-1289
31. Bousquet L., et al. Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res. Hum. Retroviruses 24 (2008) 1147-1154
32. Perloff M.D., et al. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica 34 (2004) 133-150
33. Huang L., et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos. 29 (2001) 754-760
34. Mukwaya G., et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob. Agents Chemother. 49 (2005) 4903-4910
35. Vourvahis, M. et al. (2007) Effects of tipranavir/ritonavir on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein: implications for drug interactions [abstract]. 14th Conference on Retroviruses and Opportunistic Infections, 563
36. van der Sandt I., et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier. AIDS 15 (2001) 483-491
37. Janneh O., et al. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J. Antimicrob. Chemother. 60 (2007) 987-993
38. Janneh O., et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 19 (2005) 2097-2102
39. Huisman M.T., et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16 (2002) 2295-2301
40. Dallas S., et al. Multidrug resistance protein 1-mediated transport of saquinavir by microglia. Neuroreport 15 (2004) 1183-1186
41. Anderson P.L., et al. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J. Acquir. Immune. Defic. Syndr. 42 (2006) 441-449
42. Reid G., et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol. Pharmacol. 63 (2003) 1094-1103
43. Ray A.S., et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. 50 (2006) 3297-3304
44. Mallants R., et al. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 35 (2005) 1055-1066
45. Bousquet L., et al. Emtricitabine: inhibitor and substrate of multidrug resistance associated protein. Eur. J. Pharm. Sci. 35 (2008) 247-256
46. Schuetz J.D., et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5 (1999) 1048-1051
47. Weiss J., et al. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab. Dispos 35 (2007) 340-344
48. Wang X., et al. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol. Pharmacol. 63 (2003) 65-72
49. Wang X., et al. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem. Pharmacol. 68 (2004) 1363-1370
50. Pan G., et al. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab. Dispos. 35 (2007) 1165-1173
51. Giri N., et al. Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab. Dispos. 36 (2008) 1476-1484
52. Gupta A., et al. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther. 310 (2004) 334-341
53. Weiss J., et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother. 59 (2007) 238-245
54. Hagenbuch B., and Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38 (2008) 778-801
55. Jung N., et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab. Dispos. 36 (2008) 1616-1623
56. Yao S.Y., et al. Transport of antiviral 3′-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol. Membr. Biol. 18 (2001) 161-167
57. Takeda M., et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther. 300 (2002) 918-924
58. Su Y., et al. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol. Pharm. 1 (2004) 49-56
59. Kwan, W. et al. (2008) Determining the substrate specificities of SLCO1A2 and SLCO1B1 for antiretroviral drugs [abstract]. Ninth International Workshop on Clinical Pharmacology of HIV Therapy, O4
60. Siccardi, M. et al. (2009) Is maraviroc a substrate for SLCO1B1? [abstract]. Tenth International Workshop on Clinical Pharmacology of HIV Therapy, P-02
61. Siccardi, M. et al. (2009) Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted atazanavir [abstract]. Tenth International Workshop on Clinical Pharmacology of HIV Therapy, O-04
62. Lubomirov, R. et al. (2009) Absorption, distribution, metabolism, and excretion pathway pharmacogenetics of lopinavir [abstract]. Sixteenth Conference on Retroviruses and Opportunistic Infections, 39
63. Shallcross, V. et al. (2008) Lopinavir is a substrate for SLCO1A2 but 516A>C and 38T>C polymorphisms do not influence lopinavir plasma concentrations [abstract]. Ninth International Congress on Drug Therapy in HIV Infection, P238
64. Tirona R.G., et al. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304 (2003) 223-228
65. Campbell S.D., et al. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem. Biol. Interact. 150 (2004) 179-187
66. Kis, O. et al. (2008) Interactions of HIV-1 protease inhibitors with the OATP2B1 influx transporter in Caco-2 cells [abstract]. 2008 AAPS Annual Meeting and Exposition, 1087
67. Cvetkovic M., et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27 (1999) 866-871
68. Demby, V.E. et al. (2008) OATP1B1, OATP1B3 and BCRP transporter characterization for fosamprenavir, amprenavir and lopinavir [abstract]. 2008 AAPS Annual Meeting and Exposition, 2355
69. Truong D.M., et al. Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination. J. Biol. Chem. 283 (2008) 8654-8663
70. Morita N., et al. Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J. Pharmacol. Exp. Ther. 298 (2001) 1179-1184
71. Uwai Y., et al. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res 24 (2007) 811-815
72. Bleasby K., et al. Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J. Pharmacol. Exp. Ther. 314 (2005) 923-931
73. Zhang L., et al. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab. Dispos. 28 (2000) 329-334
74. Ritzel M.W., et al. Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am. J. Physiol. 272 (1997) C707-C714
75. Cano-Soldado P., et al. Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir. Ther. 9 (2004) 993-1002
76. Lostao M.P., et al. Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes. FEBS Lett. 481 (2000) 137-140
77. Ritzel M.W., et al. Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol. Membr. Biol. 15 (1998) 203-211
78. Ritzel M.W., et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J. Biol. Chem. 276 (2001) 2914-2927
79. Sato K., et al. Influx mechanism of 2′,3′-dideoxyinosine and uridine at the blood-placenta barrier. Placenta 30 (2009) 263-269
80. Tong L., et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 51 (2007) 3498-3504
81. Cihlar T., et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir. Ther 12 (2007) 267-272
82. Kock K., et al. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin. Pharmacokinet. 46 (2007) 449-470
83. Goicoechea M., et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J. Infect. Dis. 197 (2008) 102-108
84. Ford J., et al. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob. Chemother. 54 (2004) 982-990
85. Meaden E.R., et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J. Antimicrob. Chemother. 50 (2002) 583-588
86. Ford J., et al. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48 (2004) 2388-2393
87. Lee, L. et al. (2009) Efavirenz increases MRP1 efflux transporter function while darunavir/ritonavir inhibits MRP1 expression in healthy volunteers [abstract]. Sixteenth Conference on Retroviruses and Opportunistic Infections, 705
88. Anderson P.L., et al. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS 21 (2007) 1849-1854
89. Ford J., et al. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. J. Antimicrob. Chemother. 52 (2003) 354-358
90. Chinn L.W., et al. Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein. J. Antimicrob. Chemother. 60 (2007) 61-67
91. Ronaldson P.T., et al. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection. Glia. 56 (2008) 1711-1735
92. Best B.M., et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS 23 (2009) 83-87
93. McGee B., et al. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV. Clin. Trials 7 (2006) 142-153
94. Marra C.M., et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23 (2009) 1359-1366
95. Ronaldson P.T., et al. Drug Transport in the Brain. In: You G., and Morris M.E. (Eds). Drug Transporters: Molecular Characterization and Role in Drug Disposition. 1st Edition, Chapter 14 (2007), John Wiley & Sons Inc. 411-461
96. Varatharajan L., and Thomas S.A. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 82 (2009) A99-A109
97. van Praag R.M., et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 14 (2000) 1187-1194
98. Haas D.W., et al. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob. Agents Chemother. 47 (2003) 2131-2137
99. Letendre, S.L. et al. (2007) Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin. Infect. Dis. 45
100. Solas C., et al. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47 (2003) 238-243
101. 50 in cerebrospinal fluid: CHARTER findings [abstract]. Sixteenth Conference on Retroviruses and Opportunistic Infections, 702
102. Park S., and Sinko P.J. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther. 312 (2005) 1249-1256
103. Bart J., et al. The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur. J. Cancer 40 (2004) 2064-2070
104. Augustine L.M., et al. Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. Drug Metab. Dispos. 33 (2005) 182-189
105. Taylor S., et al. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS 13 (1999) 859-860
106. Taylor S., et al. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS 14 (2000) 1979-1984
107. Taylor S., et al. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS 15 (2001) 2051-2053
108. Ghosn J., et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 18 (2004) 1958-1961
109. Finstad C.L., et al. Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions. J. Histochem. Cytochem. 38 (1990) 1677-1681
110. Dumond J.B., et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 21 (2007) 1899-1907
111. Dumond J.B., et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J. Acquir. Immune. Defic. Syndr. 51 (2009) 546-553
112. Evseenko D., et al. Active transport across the human placenta: impact on drug efficacy and toxicity. Expert. Opin. Drug Metab. Toxicol. 2 (2006) 51-69
113. Gulati A., and Gerk P.M. Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy. J. Pharm. Sci. 98 (2009) 2317-2335
114. Back D., et al. An update on therapeutic drug monitoring for antiretroviral drugs. Ther. Drug Monit. 28 (2006) 468-473